'About as true as say­ing the earth is flat': Alzheimer's ex­pert picks apart Bio­gen's Aduhelm man­u­script

Lon Schnei­der, the Uni­ver­si­ty of South Cal­i­for­nia pro­fes­sor who di­rects the Cal­i­for­nia Alzheimer’s Dis­ease Cen­ter, has been one of the most vo­cal crit­ics of Bio­gen’s de­vel­op­ment pro­gram for ad­u­canum­ab. Wary from the be­gin­ning, he picked apart the da­ta that Bio­gen pre­sent­ed along the way and, when the FDA stamped its ap­proval on Aduhelm, was among a group of ex­perts to call for its “ac­cel­er­at­ed with­draw­al” and ap­plaud­ed the CMS’ de­ci­sion to re­strict cov­er­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER